Corporate acquisitions of this magnitude require mutual agreement, strategic alignment, and complex regulatory scrutiny, and Apple historically prefers to develop proprietary technologies internally or settle disputes through licensing and litigation rather than executing multi-billion-dollar takeovers of specialized medical device firms. Furthermore, Masimo's board and shareholders ultimately elected to pursue a strategic acquisition agreement with Danaher Corporation, integrating the medical firm into a dedicated life sciences and diagnostics ecosystem instead.